Biological therapies for inherited diseases: social and bioethical considerations. Hemophilia as an example

Bibliography

• Liras A, Segovia C, Gaban SA. Advanced therapies for the treatment of hemophilia: future perspectives. Orphanet J Rare Dis 2012;7:97
   PubMedGoogle Scholar
• Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012;379:1447-56
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-47
   PubMed Web of Science ®Google Scholar
• Liras A, García-Trenchard R. Treatment for hemophilia: recombinant vs plasma-derived coagulation factors. Controversy and debate forever? An ethical medical challenge? Expert Rev Hematol 2013;6:489-92
   PubMed Web of Science ®Google Scholar
• Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011;82:91-8
   PubMed Web of Science ®Google Scholar
• De Mendoza C, Altisent C, Aznar JA, et al. Emerging Viral Infections. A Potential Threat for Blood Supply in the 21st Century. AIDS Rev 2012;14:279-89
   PubMed Web of Science ®Google Scholar
• Hermans C, Brackmann HH, Schinco P, Auerswald G. The case for wider use of recombinant factor VIII concentrates. Crit Rev Oncol Hematol 2012;83:11-20
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013;39:752-66
   PubMed Web of Science ®Google Scholar
• Liras A. Advanced therapies for hemophilia: reality or fantasy? Expert Rev Hematol 2012;5:245-7
   PubMed Web of Science ®Google Scholar
• Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy on demand: site specific regulation of gene therapy. Gene 2013;525:229-38
   PubMed Web of Science ®Google Scholar
• High KA. Gene therapy for haemophilia: a long and winding road. J Thromb Haemost 2011;9(Suppl 1):2-11
   PubMed Web of Science ®Google Scholar
• Liras A, Gaban AS, Rodriguez-Merchan EC. Cartilage restoration in haemophilia: advanced therapies. Haemophilia 2012;18:672-9
   PubMed Web of Science ®Google Scholar
• Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008;118:935-45
   PubMed Web of Science ®Google Scholar
• Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009;106:808-13
   PubMed Web of Science ®Google Scholar
• Alipio Z, Adcock DM, Waner M, et al. Sustained factor VIII production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. Blood Coagul Fibrinolysis 2010;21:502-4
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2004;10:309-18
   PubMed Web of Science ®Google Scholar
• Chuah MK, Nair N, VandenDriessche T. Recent progress in gene therapy for hemophilia. Hum Gene Ther 2012;23:557-65
   PubMed Web of Science ®Google Scholar
• Tuddenham E. Gene therapy for haemophilia B. Haemophilia 2012;18(Suppl 4):13-17
   PubMedGoogle Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65
   PubMed Web of Science ®Google Scholar
• High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012;120:4482-7
   PubMed Web of Science ®Google Scholar
• Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol 2012;2012:ID 616310
   Google Scholar
• Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr Pharm Biotechnol 2013;14:46-60
   PubMed Web of Science ®Google Scholar
• Li Z, Michael IP, Zhou D, et al. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. Proc Natl Acad Sci USA 2013;110:5004-9
   PubMed Web of Science ®Google Scholar
• Zaragosi LE, Billon N, Ailhaud G, Dani C. Nucleofection is a valuable transfection method for transient and stable transgene expression in adipose tissue-derived stem cells. Stem Cells 2007;25:790-7
   PubMed Web of Science ®Google Scholar
• Ragni MV, Sherman KE, Jordan JA. Viral pathogens. Haemophilia 2010;16(Suppl 5):40-6
   PubMedGoogle Scholar
• Stoneman P, Sturgis P, Allum N. Exploring public discourses about emerging technologies through statistical clustering of open-ended survey questions. Public Underst Sci 2013;22:850-68
   PubMed Web of Science ®Google Scholar
• Olmedillas S, Garcia-Arranz M, Garcia-Olmo D, Liras A. A first approach to non-viral gene therapy for the treatment of hemophilia B, using human mesenchymal adipose-derived stem cells and nucleofection. 2014, in editorial revision
   Google Scholar
• Gijsbers R, Ronen K, Vets S, et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 2010;18:552-60
   PubMed Web of Science ®Google Scholar
• Vets S, De Rijck J, Brendel C, et al. Transient expression of an LEDGF/p75 chimera retargets lentivector integration and functionally rescues in a model for X-CGD. Mol Ther Nucl Acids 2013;2:e77
   Google Scholar
• Du LM, Nurden P, Nurden AT, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013;4:2773
   PubMed Web of Science ®Google Scholar
• Pikuła M, Marek-Trzonkowska N, Wardowska A, et al. Adipose tissue-derived stem cells in clinical applications. Expert Opin Biol Ther 2013;13:1357-70
   PubMed Web of Science ®Google Scholar
• Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013;45:e54
   PubMed Web of Science ®Google Scholar
• Kasper CK, Buzin CH. Mosaicism and haemophilia. Haemophilia 2009;15:1181-6
   PubMedGoogle Scholar
• Kimmelman J. Staunch protections: the ethics of haemophilia gene transfer research. Haemophilia 2008;14:5-14
   PubMed Web of Science ®Google Scholar
• Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther 2007;15:1740-3
   PubMed Web of Science ®Google Scholar
• Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006;13:1031-49
   PubMed Web of Science ®Google Scholar
• Gallo-Penn A. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001;97:107-13
   PubMed Web of Science ®Google Scholar
• Herzog RW, Dobrzynski E. Immune implications of gene therapy for hemophilia. Semin Thromb Hemost 2004;30:215-26
   PubMed Web of Science ®Google Scholar
• Lillicrap D, Vandendriessche T, High K. Cellular and genetic therapies for haemophilia. Haemophilia 2006;12:36-41
   PubMed Web of Science ®Google Scholar
• Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-72
   PubMed Web of Science ®Google Scholar
• High KA. Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost 2004;30:257-67
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7
   PubMed Web of Science ®Google Scholar
• DiMichele D, Chuansumrit A, London AJ, et al. Ethical issues in haemophilia. Haemophilia 2006;12(Suppl 3):30-5
   PubMedGoogle Scholar
• Chandy M. Ethics of haemophilia care in the developing world. Haemophilia 2002;8:439-40
   PubMed Web of Science ®Google Scholar
• Declaration of Helsinki. Available from: http://www.wma.net/en/20activities/10ethics/10helsinki/index.html [Last accessed 3 January 2015]
   Google Scholar
• National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: U.S. Government Printing Office. 1978. Available from: http://videocast.nih.gov/pdf/ohrp_appendix_belmont_report_vol_2.pdf [Last accessed 3 January 2015]
   Google Scholar
• Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007;25(10):2660-9
   PubMed Web of Science ®Google Scholar
• Rogers GL, Herzog RW. Gene therapy for hemophilia. Front Biosci 2015;20:556-603
   PubMed Web of Science ®Google Scholar
• Bornstein R, Macias MI, de la Torre P, et al. Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures. Cytotherapy 2012;14(10):1182-92
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Mancuso ME. Investigational drugs for coagulation disorders. Expert Opin Investig Drugs 2013;22(8):945-53
   PubMed Web of Science ®Google Scholar
• Lambing A, Kuriakose P, Kachalsky E. Liver transplantation in the haemophilia patient. Haemophilia 2012;18(2):300-3
   PubMed Web of Science ®Google Scholar
• Kessler C, Oldenburg J, Escuriola Ettingshausen C, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management. Haemophilia 2015;21(Suppl 1):1-12
   PubMed Web of Science ®Google Scholar